The Exactech hip recall has been expanded to include an additional 40,000 components that may be faulty and prone to failure. This comes after the recall of almost 250,000 knee, hip, and ankle replacements over the previous year owing to issues with polyethylene liners.
Polyethylene particles may induce bone loss, commonly known as osteolysis, which frequently has no symptoms, however, any particle type discharged as a result of a faulty implant may exacerbate a hostile cellular reaction. Bone loss brought on by osteolysis might make revision surgery and rehabilitation more difficult. Patients with severe osteolysis may develop lifelong disability.
Exactech has already dealt with issues with its joint replacements, as seen by previous recalls. Compared to previous knee replacements, the initial Optetrak Knee System from the firm, which was debuted in 1992, has had more revisions.
Recalled Exactech Due to Liner Issues
- Product Family US Clearance Date Affected Devices Distributed in US
- Acumatch GXL September 2005 4422
- MCS GXL September 2005 238
- Novation GXL March 2007 33,654
- Exactech All Polyethylene Cemented Cup September 1996 37
- Acumatch Conventional UHMWPE November 1993 1,224
- MCS Conventional UHMWPE October 1993 28
- NOVATION Conventional UHMWPE July 2007 502
If you or a loved one has been impacted by one of the Exactech medical devices, please contact the New York attorneys at Rheingold Giuffra Ruffo Plotkin & Hellman for a free consultation today. Our experienced team has over 50 years of experience with product liability and medical malpractice cases.
David B. Rheingold, Partner
David specializes in an active trial practice primarily involving drug products, medical device liability and product liability cases. On both a state and national level, he has obtained substantial client settlements through arbitration, mediation and direct negotiations with some of the largest national and international drug and medical device makers. David has been involved in multiple high-profile legal cases including the $2.5 billion DePuy ASR and DePuy Pinnacle metal-on-metal hip implant settlement plan and the $1.4 billion Stryker Rejuvenate metal-on-metal hip implant settlement plan.
